Sorafenib, the first multikinase inhibitor demonstrated to enhance overall survival in HCC patients [299], exerts anti-angiogenic effects by inhibiting the autophosphorylation of multiple receptor tyrosine kinases, including VEGFR1, 2, and 3; PDGFRβ; c-Kit; and RET, while also inhibiting various Raf kinase isoforms [300]. This evidence concerns the gene RET and hepatocellular carcinoma.